ReviewInternational journal of breast cancer2013
Sex hormone receptor repertoire in breast cancer.
Review in International journal of breast cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role.International journal of molecular sciences · 2018Trial
- Estrogen Receptors as Key Factors in Carcinogenesis.Biomedicines · 2025Review
- Causal Link Between Thyroid Function and Female-Specific Cancers: A Bidirectional Two-Sample and Mediation Mendelian Randomization Study.International journal of women's health · 2025Article
- MiR-942-3p as a Potential Prognostic Marker of Gastric Cancer Associated with AR and MAPK/ERK Signaling Pathway.Current issues in molecular biology · 2022Article
- Lost but Not Least-Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer.Cancers · 2021Review
- The Impact of Estrogen and Estrogen-Like Molecules in Neurogenesis and Neurodegeneration: Beneficial or Harmful?Frontiers in cellular neuroscience · 2021Review
- The Emerging Role ofCancers · 2019Review
- Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.Molecular biology reports · 2019Article
- Anti-hyperplasia Effects of Total Saponins From Phytolaccae Radix in Rats With Mammary Gland Hyperplasia via Inhibition of Proliferation and Induction of Apoptosis.Frontiers in pharmacology · 2018Article
- A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Cancers · 2017Review
- Steroid hormone receptors as prognostic markers in breast cancer.American journal of cancer research · 2017Review
- An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.RNA (New York, N.Y.) · 2016Article
- Tamoxifen Resistance: Emerging Molecular Targets.International journal of molecular sciences · 2016Review
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Nature reviews. Clinical oncology · 2015Review
- What have we learned about GPER function in physiology and disease from knockout mice?The Journal of steroid biochemistry and molecular biology · 2015Review
- Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis.Journal of breast cancer · 2015Article
- Early pregnancy sex steroids and maternal breast cancer: a nested case-control study.Cancer research · 2014Article
- G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis.Molecular cancer research : MCR · 2014Article
- Nuclear receptors and pathogenesis of pancreatic cancer.World journal of gastroenterology · 2014Review
- Differential roles of ERα and ERβ in normal and neoplastic development in the mouse mammary gland.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ER α . One of the oldest recognized tumor targets, disruption of ER α -mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ER α is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ER β and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ER β -mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.